Advertisement

Journal of Diabetes & Metabolic Disorders

, Volume 17, Issue 2, pp 189–195 | Cite as

Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes

  • Arjun JainEmail author
  • Shali Chen
  • Hannah Yong
  • Subrata Chakrabarti
Research Article

Abstract

Background

Diabetes mellitus is a group of metabolic disorders in which there are high blood glucose levels over a prolonged period. Diabetes is one of many diseases associated with pathologically elevated levels of endothelin (ET)-1. We have recently proposed the development of ET-traps, which are an antibody – based fusion protein that potently bind and sequester pathologically elevated levels of endothelin-1.

Methods

We constructed ET-traps that were found to be very potent binders to ET-1, with a KD of 32.5ρM. We then treated human retinal microvascular endothelial cells (HRMECs), which are an in vitro model of glucose induced cellular damage, with 10 nM ET-1 or high glucose levels (25 mM).

Results

In this study, we investigated the effects of our ET-trap constructs on the expression levels of both collagen 4α1 and fibronectin, which are both important pathologic markers in diabetes. Treating HRMECs with 10 nM ET-1 or 25 mM glucose significantly induces the expression of the ECM proteins fibronectin and collagen 4α1, as is found in chronic diabetic complications; Incubation of the cells with the ET-traps significantly prevented the increased expression of fibronectin and collagen 4α1 back to basal levels. This was found with both mRNA and protein expression levels of the two ECM proteins.

Conclusion

Our results provide the first evidence of the efficacy of ET-traps in reducing pathologic markers in an in vitro model (of diabetes). Further research is warranted to determine the efficacy of ET-traps as a therapeutic tool for diabetes, which is a major public health burden around the world.

Keywords

DM Diabetes mellitus; ECM Extracellular matrix; ET-1 Endothelin-1; ETtr Endothelin-1 traps; FFP Fc-fusion protein; FN Fibronectin 

Notes

Author contributions

AJ and SC participated in the research design. HY and SC conducted the experiments. AJ and SC contributed new reagents or analytic tools. SC performed the data analysis. AJ, SC and SC wrote or contributed to the writing of the manuscript.

Funding

This project was funded by private funding.

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no competing interests.

Declaration statement

Any inquiries on data of this study can be directed to Dr. Arjun Jain.

References

  1. 1.
    Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 2008;29(1):42–61.CrossRefPubMedGoogle Scholar
  2. 2.
    Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.CrossRefGoogle Scholar
  3. 3.
    Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature. 2001;414(6865):792–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen S, et al. Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron. 2002;90(1):86–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen S, et al. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol. 2000;32(9):1621–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen S, et al. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab. 2003;284(6):E1089–97.CrossRefPubMedGoogle Scholar
  7. 7.
    Evans T, et al. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49(4):662–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Chen S, et al. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol. 2003;284(2):C263–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Simonson MS, Ismail-Beigi F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem. 2011;286(13):11003–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Seligman BG, et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23(9):1395–400.CrossRefPubMedGoogle Scholar
  11. 11.
    Schneider JG, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967–72.CrossRefPubMedGoogle Scholar
  12. 12.
    Stehouwer CD, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34(1):55–68.CrossRefPubMedGoogle Scholar
  13. 13.
    De Caterina, R., Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care, 2000. 3(6): p. 453–467.Google Scholar
  14. 14.
    Deanfield J, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertens. 2005;23(1):7–17.CrossRefPubMedGoogle Scholar
  15. 15.
    Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76(1):8–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Jain A, et al. Creating a soluble binder to Endothelin-1 based on the natural ligand binding domains of the Endothelin-1 (G-protein-coupled) receptor. Int J Pept Res Ther. 2017.Google Scholar
  17. 17.
    Patel S, et al. Selection of a high-affinity WW domain against the extracellular region of VEGF receptor isoform-2 from a combinatorial library using CIS display. Protein Eng Des Sel. 2013;26(4):307–15.CrossRefPubMedGoogle Scholar
  18. 18.
    Khan ZA, et al. Oncofetal fibronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45(1):287–95.CrossRefPubMedGoogle Scholar
  19. 19.
    Khan ZA, Chakrabarti S. Chronic diabetic complications: endothelial cells at the frontline. In: Rahman AU, Choudhary I, editors. Frontiers in cardiovascular drug discovery. Bentham Science publishers; 2010. p. 121–137.Google Scholar
  20. 20.
    Kaur H, et al. Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes. 2006;55(11):3104–11.CrossRefPubMedGoogle Scholar
  21. 21.
    Jain A, et al. Endothelin-1 induces endoplasmic reticulum stress by activating the PLC-IP(3) pathway: implications for placental pathophysiology in preeclampsia. Am J Pathol. 2012;180(6):2309–20.CrossRefPubMedGoogle Scholar
  22. 22.
    Manea SA, Todirita A, Manea A. High glucose-induced increased expression of endothelin-1 in human endothelial cells is mediated by activated CCAAT/enhancer-binding proteins. PLoS One. 2013;8(12):e84170.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Chen S, et al. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab Investig. 2000;80(8):1311–21.CrossRefPubMedGoogle Scholar
  24. 24.
    De Miguel, C. and J.S. Pollock, Does endoplasmic reticulum stress mediate endothelin-1-induced renal inflammation? Am J Physiol Regul Integr Comp Physiol, 2013. 305(2): p. R107–R109.Google Scholar
  25. 25.
    Jain A. Endothelin-1-induced endoplasmic reticulum stress in disease. J Pharmacol Exp Ther. 2013;346(2):163–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Jain A, Migdalska-Richards A, Jain A. Endothelin-1 -induced endoplasmic reticulum stress in Parkinson's disease. Pharmacologia. 2014;5(3):84–90.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Physiology, Development and NeuroscienceUniversity of CambridgeCambridgeUK
  2. 2.Department of PathologyUniversity of Western OntarioLondonCanada

Personalised recommendations